CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment
CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment
As part of the virtual event, Mr. Climaco will provide a brief presentation, followed by an interactive Q&A session. Investors and interested parties will have the opportunity to submit questions live during the segment. Questions can also be pre-submitted leading up to the segment by emailing cnsp@jtcir.com. Mr. Climaco will answer as many questions as possible during the segment.Live moderated webcast with John Climaco, Chief Executive Officer of CNS Pharmaceuticals on Monday, August 26th at 12:00 PM ET
CNS Pharmaceuticals首席执行官John Climaco将在2024年8月26日星期一下午12:00 ET进行现场主持的网络直播。
Participants have the ability to submit questions live during the Q&A portion of the segment or pre-submit questions in advance of the segment by emailing cnsp@jtcir.com
参与者可以在问答环节期间实时提交问题，或者通过发送电子邮件（cnsp@jtcir.com）事先提交问题。
HOUSTON, TX / ACCESSWIRE / August 22, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in a Virtual Investor CEO Connect segment on Monday, August 26, 2024 at 12:00 PM ET.
2024年8月26日星期一下午12:00 ET，CNS Pharmaceuticals（NASDAQ：CNSP）首席执行官John Climaco将参加Virtual Investor CEO Connect活动。CNS是一家生物制药公司，专门致力于为脑部和中枢神经系统的原发性和转移性癌症开发新型治疗方法，并于今天宣布了这一消息。
As part of the virtual event, Mr. Climaco will provide a brief presentation, followed by an interactive Q&A session. Investors and interested parties will have the opportunity to submit questions live during the segment. Questions can also be pre-submitted leading up to the segment by emailing cnsp@jtcir.com. Mr. Climaco will answer as many questions as possible during the segment.
作为虚拟活动的一部分，Climaco先生将进行简短的演示，并进行互动式的问答环节。投资者和感兴趣的各方将有机会在节目中实时提交问题。也可以通过电子邮件（cnsp@jtcir.com）事先提交问题。Climaco先生将在节目中尽可能回答尽可能多的问题。
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (cnspharma.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
演示的现场视频网络直播将在公司网站（cnspharma.com）的投资者页面上提供。现场演示结束后两小时，将提供网络直播重播，并可访问90天。
About CNS Pharmaceuticals, Inc.
关于CNS制药公司
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
CNS药品有限公司是一家处于临床阶段的药品公司，正在开发一系列治疗脑部和中枢神经系统原发性和转移性癌症的候选药物。公司的领先药物候选Berubicin是一种新型蒽环类似物，也是第一种似乎可以穿过血脑屏障的蒽环类似物。Berubicin当前正在开发用于治疗许多严重的脑和中枢神经系统肿瘤指标，包括恶性胶质瘤（GBM），这是一种侵袭性和不可治愈的脑癌。
For more information, please visit , and connect with the Company on X, Facebook, and LinkedIn.
欲了解更多信息，请访问X，并通过Facebook和LinkedIn与公司联系。
CONTACTS:
联系方式：
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
CNSP@jtcir.com
投资者关系联系人
JTC Team，LLC
Jenene Thomas
833-475-8247
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
信息来源：CNS制药公司。
